Vera Therapeutics
VERA
30.25
+0.83
+2.82%
Vera Therapeutics
US · VERA
#2739 by market cap
Listed 2021
30.25
+0.83
+2.82%
Live - 5344 symbols - heartbeat 286s ago
· 2026-10-08 04:00
Pre-market
30.25
0.00%
After-hours
30.00
-0.83%
- Market cap
- 2.18B
- P/E (TTM)i
- -5.15
- P/Bi
- 5.35
- EPSi
- -4.66
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on VERA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.7 percentage points.
Institutional ownership
- Held by institutions
- 117.15% -1.68pp
- Institutions
- 266 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund55.16%
Hedge Fund34.91%
VC/PE Fund18.59%
Public Company7.28%
Individual/Insider0.89%
Private Company0.84%
Government Pension Fund0.26%
Top holders as of 2026-06-30
BlackRock
7.98% · 5.75M sh
Avoro Capital Advisors LLC
7.94% · 5.72M sh
Longitude Capital Management Co., LLC
7.49% · 5.39M sh
State Street Global Advisors
5.76% · 4.15M sh
T. Rowe Price Group, Inc.
5.57% · 4.01M sh
Deep Track Capital, LP
5.55% · 4.00M sh
Deerfield Management Company, L.P.
5.43% · 3.92M sh
Vanguard Capital Management, LLC
4.47% · 3.22M sh
Kynam Capital Management, LP
4.01% · 2.89M sh
Sofinnova Investments, Inc.
3.88% · 2.79M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 16 sells
| Name | Role | Stake |
|---|---|---|
| Marshall Fordyce | Chief Executive Officer | 0.40% |
| Beth Seidenberg | Independent Director | 0.19% |
| Sean Grant | Chief Financial Officer | 0.09% |
| Joseph Young | Senior VP of Finance & Chief Accounting Officer | 0.07% |
| Jason Carter | Chief Legal Officer | 0.07% |
| Andrew Cheng | Independent Director | 0.02% |
| Laurence Skelton | -- | 0.01% |
| Robert Brenner | Chief Medical Officer | 0.01% |
| David Johnson | Chief Opearating Officer | 0.01% |
| Patrick Gerald Enright | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Marshall Fordyce | Chief Executive Officer | Derivative Exercise and Sale | -18,500 | $2.90–37.00 |
| 2026-09-10 | Joseph Young | Senior VP of Finance & Chief Accounting Officer | Derivative Exercise and Retained | +5,000 | $3.94 |
| 2026-09-01 | Marshall Fordyce | Chief Executive Officer | Derivative Exercise and Sale | -18,500 | $2.90–35.12 |
| 2026-08-02 | Nancy Boman | -- | Other Acquisition | +44,987 | -- |
| 2026-08-02 | Nancy Boman | -- | Other Derivative Acquisition | +63,011 | $32.23 |
| 2026-07-06 | Marshall Fordyce | Chief Executive Officer | Derivative Exercise and Sale | -46,250 | $2.90–43.59 |
| 2026-06-22 | Marshall Fordyce | Chief Executive Officer | Derivative Exercise and Sale | -18,500 | $2.90–38.43 |
| 2026-05-20 | Michael Morrissey | Independent Chairperson | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | Patrick Gerald Enright | Independent Director | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | Beth Seidenberg | Independent Director | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | Scott William Morrison | Independent Director | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | James Meyers | Director | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | Andrew Cheng | Independent Director | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | Christy Oliger | Director | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-20 | Kimball Hall | -- | Other Derivative Acquisition | +17,084 | $34.35 |
| 2026-05-11 | Marshall Fordyce | Chief Executive Officer | Derivative Exercise and Sale | -18,500 | $2.90–37.09 |
| 2026-04-13 | Marshall Fordyce | Chief Executive Officer | Automatic Disposition | -22,951 | $43.66–45.51 |
| 2026-03-22 | Jane Wright-Mitchell | Chief Legal Officer | Other Acquisition | +42,403 | -- |
| 2026-03-22 | Jane Wright-Mitchell | Chief Legal Officer | Other Derivative Acquisition | +56,850 | $40.73 |
| 2026-03-12 | Joseph Young | Senior VP of Finance & Chief Accounting Officer | Derivative Exercise and Retained | +10,000 | $3.94 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:00:01 · For reference only, not investment advice and not tailored to your situation.